- Q1. What is the business of Mahamaya lifesciences?Mahamaya Lifesciences is primarily engaged in the manufacturing, registration, and marketing of pesticide formulations and biological products aimed at crop protection and soil health management.
- Q2. Why is the company raising funds via IPO?Mahamaya Lifesciences is raising funds via its IPO to invest in expanding manufacturing capacity by purchasing new equipment and setting up a new technical-grade pesticide plant, constructing warehouse infrastructure, meeting working capital needs, and supporting general corporate purposes.
- Q3. What is the size of the issue and where will it list?The issue size is 70.44 Crore and It will be listed on BSE-SME.
- Q4. What are the risks of investing in this Mahamaya Lifesciences IPO?Investment risks in Mahamaya Lifesciences IPO include high dependency on a few large customers, lack of long-term supply agreements, raw material price volatility, regulatory approval uncertainties, seasonal demand affecting revenue, liquidity strains due to rising inventory and receivables, and competition from larger players.
- Q5. What are the potential upsides?Potential upsides of Mahamaya Lifesciences include strong revenue growth, expanding dealer and export network, focus on eco-friendly bio-based products, increasing production capacity, and benefiting from rising global demand for sustainable agriculture solutions.
Mahamaya lifesciences (NEW IPO): GMP today, Price, Review, Detail
Closed
14 July 2026
0
Rating
Mahamaya Lifesciences Limited specializes in the manufacturing, marketing, and export of crop protection products and bioproducts for agriculture and soil health management.Mahamaya Lifesciences is known for its strong branding portfolio with key products like MAYAMECTIN, MAYAIMIDA, MAYAPRID, and others, and maintains a dealer network of over 310 across India. consists of a fresh issue of up to 56,38,800 equity shares and an offer for sale of up to 5,40,000 equity shares, with a total issue size of ₹70.44 crore at the upper price band.
Mahamaya lifesciences was incorporated in the year 2002.The Managing Director of Mahamaya Lifesciences is Mr. Krishnamurthy Ganesan and Mrs. lalitha krishnamurthy.
Mahamaya Lifesciences Limited’s IPO subscription date was in opening on Nov 11, 2025 and closes on Nov 13, 2025, with The allotment for the Mahamaya Lifesciences IPO is expected to be finalized on Nov 14, 2025.
The price range of the IPO was set between approximately ₹108 to ₹114 per equity share.The lot size for an application is 1,200. The minimum amount of investment required by an individual investor (retail) is ₹2,73,600.00 (2,400 shares) (based on upper price)
Revenue, PAT, EBITDA
|
Year
|
2025
|
|---|---|
|
Networth
|
~ ₹ 53.50 Cr
|
|
Revenue
|
~ ₹ 267.17 Cr
|
|
EBITDA
|
~ ₹ 24.64 Cr
|
|
PAT
|
~ ₹ 12.9 Cr
|
|
EBITDA Margin
|
~9.22%
|
|
PAT Margin
|
~4.84%
|
|
Face Value
|
10
|
IPO Important Dates
|
#
|
Date
|
|---|---|
|
Open Date
|
Tuesday, November 11, 2025
|
|
Close Date
|
Thursday, November 13, 2025
|
|
Anchor Investor Bidding
|
Monday, November 10, 2025
|
|
Allotment Date
|
Friday, November 14, 2025
|
|
Refunds& Demat Credit
|
Monday, November 17, 2025
|
|
Tentative Listing Date
|
18-Nov'25
|
Use Of Proceeds
|
Purpose
|
Amount
|
|---|---|
|
Working Capital Requirements
|
~ ₹ 18 Crore
|
|
Subsidiary acquisition
|
|
|
Borrowing prepayment/repayment
|
|
|
General Corporate Purpose
|
Balance
|
Financial Data
|
#
|
2023
|
2024
|
2025
|
|---|---|---|---|
|
Revenue (₹ Cr)
|
₹ 137.4
|
₹ 162.8
|
₹ 267.2
|
|
PAT (₹ Cr)
|
₹ 3.8
|
₹ 5.2
|
₹ 12.9
|
|
Asset (₹ Cr)
|
₹ 77.9
|
₹ 112.1
|
₹ 188.4
|
|
Net Worth (₹ Cr)
|
₹ 19.4
|
₹ 24.7
|
₹ 53.5
|
IPO Grey Market Premium
|
Date
|
IPO Price
|
IPO GMP
|
Profit Per Lot
|
|---|---|---|---|
|
17-Jun
|
₹ –
|
₹ –
|
₹ –
|
|
16-Jun
|
₹ –
|
₹ –
|
₹ –
|
|
15-Jun
|
₹ –
|
₹ –
|
₹ –
|
|
14-Jun
|
₹ –
|
₹ –
|
₹ –
|
|
13-Jun
|
₹ –
|
₹ –
|
₹ –
|
Promoters – Pre offer equity (Approx)
|
Promoters
|
% Shares
|
|---|---|
|
Mr. Krishnamurthy Ganesan
|
~30.88 %
|
|
Mrs. Lalitha Krishnamurthy
|
~23.20%
|
|
Mr. Prashant Krishnamurthy
|
~23.20%
|
|
-
|
-
|
|
-
|
-
|
|
-
|
-
|
Lot Size details
|
Application Type
|
Lot Size
|
No. of Lot
|
No. of Shares
|
Investment Amount
|
|---|---|---|---|---|
|
Retail (Min)
|
1,200
|
7
|
8,400
|
₹ –
|
|
Retail (Max)
|
₹ 957,600
|
13
|
–
|
₹ –
|
|
HNI (Min)
|
–
|
14
|
–
|
₹ –
|
|
HNI (Max)
|
–
|
66
|
–
|
₹ –
|
|
Big HNI (Min)
|
–
|
67
|
–
|
₹ –
|
Key Performance Index (KPI)
|
ROE
|
00
|
|---|---|
|
ROCE
|
00
|
|
RoNW
|
26.58%
|
